Cytosorbents Corporation (CTSO)
| Bid | 0.95 |
| Market Cap | 55.38M |
| Revenue (ttm) | 37.22M |
| Net Income (ttm) | -18.8M |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -2.81 |
| Forward PE | -7.14 |
| Analyst | Buy |
| Ask | 1.2 |
| Volume | 45,156 |
| Avg. Volume (20D) | 246,063 |
| Open | 1.03 |
| Previous Close | 1.00 |
| Day's Range | 0.99 - 1.07 |
| 52-Week Range | 0.70 - 1.61 |
| Beta | 0.78 |
About CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complication...
Analyst Forecast
According to 4 analyst ratings, the average rating for CTSO stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 543.56% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago · seekingalpha.com
Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call TranscriptCytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Confer...